Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
64.5M
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
50.6M
-
Shares change
-
+3.84M
-
Total reported value, excl. options
-
$202M
-
Value change
-
+$62.7M
-
Put/Call ratio
-
0
-
Number of buys
-
45
-
Number of sells
-
-75
-
Price
-
$4.00
Significant Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) as of Q2 2025
136 filings reported holding INZY - Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share as of Q2 2025.
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.6M shares
of 64.5M outstanding shares and own 78.37% of the company stock.
Largest 10 shareholders include Beryl Capital Management LLC (6.32M shares), Pivotal bioVenture Partners Investment Advisor LLC (4.49M shares), GLAZER CAPITAL, LLC (4.33M shares), Sofinnova Investments, Inc. (4.28M shares), ODDO BHF ASSET MANAGEMENT SAS (3.2M shares), Trium Capital LLP (3.17M shares), BlackRock, Inc. (2.66M shares), VANGUARD GROUP INC (2.5M shares), NEA Management Company, LLC (2.44M shares), and ALPINE ASSOCIATES MANAGEMENT INC. (2.19M shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.